Patients with Chronic Obstructive Pulmonary Disease (COPD) should be careful about the inhalers they use. A new study has found that a popular class of anti-inflammatory inhalers, after prolonged usage, could considerably hike the risk of pneumonia in these patients.
COPD is a progressive disease that makes it hard to breathe and is characterised by coughing that produces large amounts of mucus, wheezing, shortness of breath, chest tightness and other symptoms.
The research by Wake Forest University School of Medicine scientists mainly deals with the incidence of pneumonia in COPD patients, who were exposed to inhaled corticosteroid drugs, either alone or in combination with other drugs.
While inhaled corticosteroids, used alone or in combination with other drugs for the treatment of asthma, have not been approved for use in patients with COPD, it has been suggested in combination with beta-antagonists, which dilate the lungs.
The available inhaled steroid combinations are fluticasone/salmeterol, marketed byGlaxoSmithKline as AdvairTM, and budesonide/formoterol, marketed by AstraZeneca as SymbicortTM.
Although, the inhalers can successfully relieve many of the symptoms of COPD, they have been linked with an increased risk of pneumonia in recent studies.
In the current study, researchers reviewed 18 randomized clinical trials, several of which were unpublished, involving nearly 17,000 patients in total.
They compared the incidence of pneumonia in patients who had taken inhaled corticosteroids for at least 24 weeks versus patients who had taken a placebo, or patients who had taken combination inhaled corticosteroids and long-acting beta-antagonists versus patients who took only the long-acting bronchodilator.